Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$1.22 -3.9%	$1.48	$1.11 ▼ $5.00	$324.69M	1.77	1.47 million shs	1.98 million shs
CMPS COMPASS Pathways	$3.86 -1.0%	$3.34	$2.49 ▼ $8.54	$358.40M	2.27	802,012 shs	492,520 shs
ORKA Oruka Therapeutics	$9.71 +0.9%	$9.93	$5.49 ▼ $31.13	$363.55M	0.25	229,448 shs	116,273 shs
ORMP Oramed Pharmaceuticals	$2.21 -1.3%	$2.26	$1.82 ▼ $3.09	$90.28M	1.65	153,881 shs	45,615 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	-5.93%	+7.17%	-6.62%	-35.20%	-68.33%
CMPS COMPASS Pathways	-0.26%	+7.14%	+36.84%	-8.24%	-51.97%
ORKA Oruka Therapeutics	-1.33%	+3.55%	+25.26%	-18.96%	+961,999,900.00%
ORMP Oramed Pharmaceuticals	0.00%	+0.45%	+6.16%	-9.31%	-7.05%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUTL Autolus Therapeutics	3.0105 of 5 stars	3.5	3.0	2.5	3.3	0.6
CMPS COMPASS Pathways	1.774 of 5 stars	3.5	1.0	2.7	0.8	0.6
ORKA Oruka Therapeutics	3.261 of 5 stars	3.6	0.0	3.2	4.2	0.6
ORMP Oramed Pharmaceuticals	2.091 of 5 stars	0.0	5.0	2.6	0.8	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUTL Autolus Therapeutics	3.00	Buy	$9.32	663.93% Upside
CMPS COMPASS Pathways	3.00	Buy	$20.20	423.32% Upside
ORKA Oruka Therapeutics	3.22	Buy	$39.86	310.48% Upside
ORMP Oramed Pharmaceuticals	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest ORMP, ORKA, CMPS, and AUTL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/12/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $45.00
4/10/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/1/2025	AUTL Autolus Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
3/28/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/21/2025	AUTL Autolus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$8.00 ➝ $6.00
3/7/2025	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$40.00
3/4/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $45.00
2/28/2025	CMPS COMPASS Pathways	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $15.00
2/27/2025	CMPS COMPASS Pathways	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$11.00

(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUTL Autolus Therapeutics	$9.01M	36.03	N/A	N/A	$0.64 per share	1.91
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	$3.65 per share	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
ORMP Oramed Pharmaceuticals	$1.34M	67.37	N/A	N/A	$4.04 per share	0.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUTL Autolus Therapeutics	-$208.38M	-$0.88	N/A	N/A	N/A	N/A	-63.65%	-36.54%	N/A
CMPS COMPASS Pathways	-$118.46M	-$1.99	N/A	N/A	N/A	N/A	-63.85%	-51.97%	N/A
ORKA Oruka Therapeutics	-$5.34M	-$5.79	N/A	N/A	N/A	N/A	-24.96%	-21.22%	5/15/2025 (Estimated)
ORMP Oramed Pharmaceuticals	$5.53M	-$0.21	20.09	N/A	N/A	N/A	-7.27%	-6.20%	5/15/2025 (Estimated)

Latest ORMP, ORKA, CMPS, and AUTL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	N/A	ORMP Oramed Pharmaceuticals	-$0.03	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	ORKA Oruka Therapeutics	-$0.57	-$0.40	+$0.17	-$0.40	N/A	N/A
5/8/2025	Q1 2025	AUTL Autolus Therapeutics	-$0.24	-$0.26	-$0.02	-$0.26	$1.59 million	$8.98 million
5/8/2025	Q1 2025	CMPS COMPASS Pathways	-$0.47	-$0.44	+$0.03	-$0.24	N/A	N/A
3/27/2025	Q4 2024	ORMP Oramed Pharmaceuticals	-$0.03	$0.01	+$0.04	$0.01	N/A	N/A
3/20/2025	Q4 2024	AUTL Autolus Therapeutics	-$0.21	-$0.09	+$0.12	-$0.09	$2.98 million	$0.03 million
3/6/2025	Q4 2024	ORKA Oruka Therapeutics	-$0.68	-$0.49	+$0.19	-$0.49	N/A	N/A
2/27/2025	Q4 2024	CMPS COMPASS Pathways	-$0.62	-$0.63	-$0.01	-$0.63	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A
ORMP Oramed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUTL Autolus Therapeutics	N/A	13.69	13.69
CMPS COMPASS Pathways	0.15	8.91	8.91
ORKA Oruka Therapeutics	N/A	22.89	22.89
ORMP Oramed Pharmaceuticals	N/A	27.08	27.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUTL Autolus Therapeutics	72.83%
CMPS COMPASS Pathways	46.19%
ORKA Oruka Therapeutics	56.44%
ORMP Oramed Pharmaceuticals	12.73%

Insider Ownership

Company	Insider Ownership
AUTL Autolus Therapeutics	25.70%
CMPS COMPASS Pathways	4.25%
ORKA Oruka Therapeutics	22.67%
ORMP Oramed Pharmaceuticals	13.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUTL Autolus Therapeutics	330	266.14 million	197.71 million	Optionable
CMPS COMPASS Pathways	120	92.85 million	65.51 million	Optionable
ORKA Oruka Therapeutics	N/A	37.44 million	27.07 million	N/A
ORMP Oramed Pharmaceuticals	10	40.85 million	34.79 million	Optionable

ORMP, ORKA, CMPS, and AUTL Headlines

Recent News About These Companies

StockNews.com Downgrades Oramed Pharmaceuticals (NASDAQ:ORMP) to Sell

May 11 at 3:53 AM | marketbeat.com

Oramed Pharmaceuticals (NASDAQ:ORMP) Downgraded by StockNews.com to Sell

May 9, 2025 | americanbankingnews.com

Oramed Pharmaceuticals (ORMP) to Release Earnings on Thursday

May 3, 2025 | marketbeat.com

Oramed Pharmaceuticals Inc.: Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

April 28, 2025 | finanznachrichten.de

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

April 28, 2025 | globenewswire.com

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

April 28, 2025 | prnewswire.com

Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Crosses Below 200-Day Moving Average - Here's Why

April 25, 2025 | marketbeat.com

Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Passes Below Two Hundred Day Moving Average - Time to Sell?

April 16, 2025 | marketbeat.com

ORMP: Upcoming Expected Milestones Include OraTech Spin-Off & IPO, Launch of Phase 3 Trial

April 3, 2025 | finance.yahoo.com

Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential

March 15, 2025 | finance.yahoo.com

Oramed Pharmaceuticals Issues Letter to Shareholders

March 4, 2025 | prnewswire.com

OraMed Enters Global Licensing Deal for Lidocaine Product

March 1, 2025 | investing.com

Congressional Trading Report: Rep. Brad Knott Sold Over $15K In Oramed Pharmaceuticals Stock

February 27, 2025 | benzinga.com

Oramed Pharmaceuticals to Spin Off Its Protein Oral Delivery Technology

February 11, 2025 | contractpharma.com

OraTech to pioneer oral insulin with $75 million investment

February 11, 2025 | msn.com

Oramed enters JV for insulin development and commercialization

February 11, 2025 | markets.businessinsider.com

Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin

February 11, 2025 | prnewswire.com

Scilex announces early installment payment on senior secured promissory note

December 16, 2024 | markets.businessinsider.com

ORMP: Preparations for New Phase 3 Trial Advance, While ORMP Leverages Balance Sheet Through Recent Agreements

December 2, 2024 | finance.yahoo.com

Oramed Pharm (ORMP) Receives a Hold from H.C. Wainwright

September 9, 2024 | markets.businessinsider.com

ORMP: Balance Sheet Strong, Potential Benefits of Investments, JVs, Buybacks

August 30, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP, ORKA, CMPS, and AUTL Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

$1.22 -0.05 (-3.94%)

As of 04:00 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

COMPASS Pathways NASDAQ:CMPS

$3.86 -0.04 (-1.03%)

As of 04:00 PM Eastern

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Oruka Therapeutics NASDAQ:ORKA

$9.71 +0.09 (+0.94%)

As of 04:00 PM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Oramed Pharmaceuticals NASDAQ:ORMP

$2.21 -0.03 (-1.34%)

As of 04:00 PM Eastern

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time